Volume 42, Issue 5, Pages (June 2011)

Slides:



Advertisements
Similar presentations
UV as an Amplifier Rather Than Inducer of NF-κB Activity
Advertisements

Volume 35, Issue 4, Pages (August 2009)
Plk1 Controls the Nek2A-PP1γ Antagonism in Centrosome Disjunction
Volume 36, Issue 5, Pages (December 2009)
Negative Regulation of Vps34 by Cdk Mediated Phosphorylation
The Unique N Terminus of the UbcH10 E2 Enzyme Controls the Threshold for APC Activation and Enhances Checkpoint Regulation of the APC  Matthew K. Summers,
Volume 27, Issue 4, Pages (August 2007)
Volume 35, Issue 3, Pages (August 2009)
Cell Cycle-Regulated Phosphorylation of p21-Activated Kinase 1
Cdk2 Kinase Is Required for Entry into Mitosis as a Positive Regulator of Cdc2–Cyclin B Kinase Activity  Thomas M Guadagno, John W Newport  Cell  Volume.
Phosphorylation of Cdc20 by Bub1 Provides a Catalytic Mechanism for APC/C Inhibition by the Spindle Checkpoint  Zhanyun Tang, Hongjun Shu, Dilhan Oncel,
Yan Jiang, Mingyi Liu, Charlotte A. Spencer, David H. Price 
Volume 16, Issue 1, Pages (October 2004)
Volume 47, Issue 1, Pages (July 2012)
Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase  Rémi Buisson, Jessica L. Boisvert, Cyril H. Benes,
Decreased Growth Inhibitory Responses of Squamous Carcinoma Cells to Interferon-γ Involve Failure to Recruit cki Proteins into cdk2 Complexes  Beth L.
Volume 22, Issue 1, Pages (January 2012)
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Volume 29, Issue 3, Pages (February 2008)
Plk1 Controls the Nek2A-PP1γ Antagonism in Centrosome Disjunction
A Cdk7-Cdk4 T-Loop Phosphorylation Cascade Promotes G1 Progression
The Cdk-Activating Kinase (CAK) from Budding Yeast
JNK2 Is a Positive Regulator of the cJun Transcription Factor
Volume 6, Issue 3, Pages (September 2000)
Cdc7-Dbf4 Phosphorylates MCM Proteins via a Docking Site-Mediated Mechanism to Promote S Phase Progression  Yi-Jun Sheu, Bruce Stillman  Molecular Cell 
Volume 35, Issue 3, Pages (August 2009)
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Volume 32, Issue 5, Pages (December 2008)
Volume 17, Issue 1, Pages (January 2005)
Yutian Peng, Lois S. Weisman  Developmental Cell 
Positive or Negative Roles of Different Cyclin-Dependent Kinase Pho85-Cyclin Complexes Orchestrate Induction of Autophagy in Saccharomyces cerevisiae 
Volume 11, Issue 1, Pages (July 1999)
Volume 56, Issue 5, Pages (December 2014)
Ken-ichi Yoshioka, Yoshiko Yoshioka, Peggy Hsieh  Molecular Cell 
Laura Lande-Diner, Jianmin Zhang, Howard Cedar  Molecular Cell 
The Actin-Bundling Protein Palladin Is an Akt1-Specific Substrate that Regulates Breast Cancer Cell Migration  Y. Rebecca Chin, Alex Toker  Molecular.
Volume 24, Issue 3, Pages (November 2006)
A Critical Role for Noncoding 5S rRNA in Regulating Mdmx Stability
Phosphorylation on Thr-55 by TAF1 Mediates Degradation of p53
Molecular Basis of Drug Resistance in Aurora Kinases
Junbiao Dai, Weiwu Xie, Troy L. Brady, Jiquan Gao, Daniel F. Voytas 
E. Josué Ruiz, Marçal Vilar, Angel R. Nebreda  Current Biology 
Yi Tang, Jianyuan Luo, Wenzhu Zhang, Wei Gu  Molecular Cell 
Volume 26, Issue 6, Pages (June 2007)
Volume 39, Issue 2, Pages (July 2010)
CTLA-4 Regulates Induction of Anergy In Vivo
Volume 20, Issue 3, Pages (July 2017)
Volume 1, Issue 4, Pages (March 1998)
Volume 8, Issue 6, Pages (December 2005)
Volume 54, Issue 6, Pages (June 2014)
Richard W. Deibler, Marc W. Kirschner  Molecular Cell 
Volume 14, Issue 2, Pages (August 2008)
Volume 47, Issue 4, Pages (August 2012)
Cdc18 Enforces Long-Term Maintenance of the S Phase Checkpoint by Anchoring the Rad3-Rad26 Complex to Chromatin  Damien Hermand, Paul Nurse  Molecular.
Volume 9, Issue 3, Pages (March 2002)
Lindsey A. Allan, Paul R. Clarke  Molecular Cell 
Volume 49, Issue 6, Pages (March 2013)
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Yan Jiang, Mingyi Liu, Charlotte A. Spencer, David H. Price 
Regulation of Yeast mRNA 3′ End Processing by Phosphorylation
Volume 27, Issue 4, Pages (August 2007)
RhoA GTPase Regulates B Cell Receptor Signaling
Volume 39, Issue 2, Pages (July 2010)
Volume 33, Issue 6, Pages (March 2009)
A CDK-Independent Function of Mammalian Cks1
Meiotic Inactivation of Xenopus Myt1 by CDK/XRINGO, but Not CDK/Cyclin, via Site- Specific Phosphorylation  E. Josué Ruiz, Tim Hunt, Angel R. Nebreda 
Volume 28, Issue 1, Pages (January 2008)
Volume 41, Issue 4, Pages (February 2011)
Cdk1 Negatively Regulates Midzone Localization of the Mitotic Kinesin Mklp2 and the Chromosomal Passenger Complex  Stefan Hümmer, Thomas U. Mayer  Current.
Yun-Gui Yang, Tomas Lindahl, Deborah E. Barnes  Cell 
Presentation transcript:

Volume 42, Issue 5, Pages 624-636 (June 2011) Switching Cdk2 On or Off with Small Molecules to Reveal Requirements in Human Cell Proliferation  Karl A. Merrick, Lara Wohlbold, Chao Zhang, Jasmina J. Allen, Dai Horiuchi, Noelle E. Huskey, Andrei Goga, Kevan M. Shokat, Robert P. Fisher  Molecular Cell  Volume 42, Issue 5, Pages 624-636 (June 2011) DOI: 10.1016/j.molcel.2011.03.031 Copyright © 2011 Elsevier Inc. Terms and Conditions

Molecular Cell 2011 42, 624-636DOI: (10.1016/j.molcel.2011.03.031) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 1 Cdk2 Activity Is Required for Human Cell Proliferation (A) The Cdk2 locus was targeted by an rAAV vector containing a neomycin-resistance (neoR) cassette bounded by loxP sites and homologous arms, as indicated. The F80G mutation and EcoRI site used for genotyping were introduced in exon 3. (B) RPE-hTERT cells with varying amounts of total and AS Cdk2, quantified by immunoblot. (C) HCT116 and RPE-hTERT whole-cell extract proteins were labeled by endogenously expressed Cdk2as with [γ-32P]N6-(benzyl)-ATP. (D) RPE-hTERT cells of the indicated genotype were grown for 7 days in the presence of increasing amounts of 3-MB-PP1. Cells were fixed and stained with crystal violet solution. (E) RPE-hTERT cells of the indicated genotype were treated with DMSO or 1 μM 3-MB-PP1 for 48 hr prior to seeding. Cells were maintained in DMSO or, if pretreated with 1 μM 3-MB-PP1, switched to 10 μM 3-MB-PP1, and cell number was determined every 24 hr. Each data point is the mean ± SEM of three independent plates of cells. Molecular Cell 2011 42, 624-636DOI: (10.1016/j.molcel.2011.03.031) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 2 Cdk2as Has Cyclin A Binding and T Loop Phosphorylation Defects In Vivo (A) Wild-type and Cdk2as/as HCT116 cells were treated with DMSO or indicated concentration of 3-MB-PP1 for 96 hr. Cyclin A was immunoprecipitated from extracts, and immune complexes were denatured by boiling in 1% SDS. The supernatants were diluted, Cdk1 and Cdk2 were immunoprecipitated, and the amount of each CDK recovered was determined by immunoblotting with PSTAIRE antibody. (B) Same as (A) except that first immunoprecipitation was of cyclin E. (C) Wild-type and Cdk2as/as RPE-hTERT cells were synchronized by contact inhibition and released into increasing concentrations of 3-MB-PP1. Amounts of cyclin A, total Cdk2, and Cdk2-Thr160 phosphorylation were determined by immunoblotting—the last both by electrophoretic mobility shift and with Cdk2-Thr160-P specific antibodies. Molecular Cell 2011 42, 624-636DOI: (10.1016/j.molcel.2011.03.031) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 3 Chemical Rescue of Cdk2as by 6-BAP (A) Wild-type and Cdk2as/as RPE-hTERT cells were synchronized by contact inhibition and released for 27 hr into medium containing DMSO, 1 μM 3-MB-PP1, or 10 μM of indicated compound. Cyclin A and Cdk2 were detected by immunoblotting, and rescue of Cdk2as was assessed by calculating ratio of phosphorylated-to-unphosphorylated Cdk2 in each extract. (B) Cells synchronized as in (A) were released into indicated concentration of 3-MB-PP1 or 6-BAP, collected after 25 hr, and phosphorylated-to-unphosphorylated Cdk2 ratio was determined. (C) The ability of 6-BAP to restore normal cyclin A pairing was determined as in Figure 2A. (D) Extracts from (C) were labeled with [γ-32P]N6-(benzyl)-ATP to determine effect of treating cells with 6-BAP on amount of active Cdk2as in extracts. (E) Cdk2as/cyclin A and Cdk2WT/cyclin A complexes were tested for sensitivity to 3-MB-PP1 by incubation with increasing concentrations of drug prior to histone H1 kinase assay. IC50 for Cdk2as/cyclin A is ∼3 nM. (F) As in (E) for 3-MB-PP1, IC50 of 6-BAP for Cdk2as/cyclin A was determined to be ∼1 μM. Molecular Cell 2011 42, 624-636DOI: (10.1016/j.molcel.2011.03.031) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 4 Two Defects in Cdk2as Activation Lead to Aberrant CDK/Cyclin Pairing (A) A mathematical model of CDK activation (see Figure S4 and Supplemental Experimental Procedures for details) was used to test effects of perturbing different parameters on cyclin pairing. The ratio of Cdk2/cyclin A to Cdk1/cyclin A at the end of each simulation (dashed line on left) was calculated and plotted as a function of changing the activation parameters, Cdk2-cyclin A affinity (“Kf Cdk2-CycA”), and rate of Cdk2 monomer phosphorylation (“Vmax Cdk2 monomer phosphorylation”), as indicated. (B) To test cyclin A selectivity in vitro, an ATP-regenerating system and a limiting amount of purified His-tagged cyclin A were added to extracts of wild-type or Cdk2as/as HCT116 cells. After a 1 hr incubation, His-cyclin A-associated proteins were recovered by Ni2+ affinity, and amounts of bound Cdk1 and Cdk2 determined by immunoblotting. Where indicated, 1 μM 3-MB-PP1 was added to extracts 1 hr prior to cyclin A and ATP. (C) Cyclin A selectivity was tested as in (B), except where indicated 1 μM 6-BAP was added to extracts 1 hr prior to cyclin A and ATP. In lane 7, 1 μM 6-BAP was also included in buffers for pull-down and wash steps. (D) Extracts from wild-type and Cdk2as/as HCT116 cells were fractionated in a Superdex 200 sizing column, and Cdk2 monomer fractions were pooled and immunoblotted with antibodies for Cdk2 and Cdk2-Thr160P. (E) Cdk2 monomer populations from (D) were immunoprecipitated and treated with either Cdk7 complex or S. pombe Csk1. Increased phosphorylation was detected by mobility shift of Cdk2. Molecular Cell 2011 42, 624-636DOI: (10.1016/j.molcel.2011.03.031) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 5 A More Stringent Cdk2 Activity Requirement When Growth Factors Are Limiting (A) Wild-type or Cdk2as/as RPE-hTERT cells were grown in 1% or 10% serum-containing medium with DMSO or 1 μM 3-MB-PP1, and cell number was determined every 24 hr. Cells were pretreated with DMSO or 1 μM 3-MB-PP1 for 48 hr as in Figure 1E. Each data point is the mean ± SEM of three independent plates of cells. (B) Cdk2as/as HCT116 cells were synchronized in G0/G1 by serum starvation and released into medium containing 1% serum, nocodazole, and DMSO or 10 μM 3-MB-PP1. Cells were collected at indicated times, and cell-cycle distribution was determined by flow cytometric analysis of DNA content. (C) Cdk2as/as HCT116 cells synchronized as in (B) were analyzed for pocket protein phosphorylation by immunoblotting with indicated antibodies. (D) Cdk2as/as HCT116 cells were synchronized as in (B) and released into medium containing 1% or 10% serum and DMSO or 10 μM 3-MB-PP1. Phosphorylation of p130 was detected by mobility shift in immunoblots with pan-specific antibodies. Molecular Cell 2011 42, 624-636DOI: (10.1016/j.molcel.2011.03.031) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 6 Manipulating Cdk2 with Small Molecules Uncovers a Nonredundant Role in R Point Control (A) Wild-type and Cdk2as/as RPE-hTERT cells were synchronized in G0 by contact inhibition and released into medium containing nocodazole, BrdU, the indicated concentration of serum, and DMSO, 0.5 μM 6-BAP or 10 μM 3-MB-PP1. Cells were fixed 40 hr after release and stained to detect BrdU incorporation. (B) Wild-type and Cdk2as/as RPE-hTERT cells were synchronized in G0 by contact inhibition and released into 10% serum-containing medium supplemented with BrdU and DMSO, 0.5 μM 6-BAP or 10 μM 3-MB-PP1, for 9, 12, 16, or 20 hr. Cells were washed and changed to serum-free medium containing BrdU while maintaining drug treatment. Cells were fixed 40 hr after release and stained to detect BrdU incorporation. (C) R point passage was determined as in (B), except that when cells were transferred from 10% to 0% serum, drug treatment was switched from 3-MB-PP1 to 6-BAP (orange bars) or from 6-BAP to 3-MB-PP1 (dark-green bars). Each data point is the mean ± SEM of four fields of cells. Molecular Cell 2011 42, 624-636DOI: (10.1016/j.molcel.2011.03.031) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 7 Cdk2as: A Three-Position Switch to Regulate R Point Passage with Small Molecules Cdk2as has activation defects in untreated cells, leading to lower abundance of Cdk2/cyclin A complexes and impaired R point control. From this partially active state, Cdk2as can be turned on or off, respectively, with the small molecules 6-BAP or 3-MB-PP1—both of which correct conformation but with opposite effects on catalytic activity—to uncover a rate-limiting role of Cdk2 in pocket protein phosphorylation, R point passage, and S phase entry. Molecular Cell 2011 42, 624-636DOI: (10.1016/j.molcel.2011.03.031) Copyright © 2011 Elsevier Inc. Terms and Conditions